Your post recommended. Of course if discussions with a USA based Pharma are proceeding, if this leads to some rights resting in the USA, Immunobody / SCIB 1 might soon benefit from the FDA 'Fast Track Development Program' ? (Assuming that vaccines are eligible, as well as drugs). BoD are focused and too busy for Biotrinity. Good. An RNS would be good..........
Interesting review from Lady Bio. The last para is rather powerful. Roll on the next update from Phase 2 trials. Do you know if the 3 ladies from the University are working for Scancell on a Consultancy basis or are they Associates in some way ? I hope they each have a good shareholding.
Here's an interesting reply about that article linked to by johnson36 yesterday. It was given to a poster called Simon on DTM Scancell Chat by the resident guru LadyBio:
Simon - Immunotherapy is a buzz word in the industry at the moment and is frequently used for cancer products that are wholly unrelated to one another; the only connection being that they target some part of the highly complex human immune system. As Puritas on LSE pointed out, the article was NOT about cancer vaccines and therefore did not deal with either Scancell or any of its immediate competition such as fellow cancer vaccine firms Dendreon, Northwest Biotherapeutics or Oncothyreon.
The article dealt narrowly with one area of an extensive class of drugs called inhibitors. They seek to inhibit some physiological or genetic pathway in the body in an attempt to treat various conditions including cancers. The inhibitors featured were PD-1 inhibitors. PD-1 is a protein that is believed to block the production of the immune system's cancer fighting T-Cells. It is suspected that certain types of cancer can use PD-1 to protect themselves from being attacked by T Cells. So the industry is attempting to inhibit PD-1 to allow the immune system to regain the advantage.
Nivolumab from Bristol-Myers Squibb is one of the latest PD-1 inhibitors showing promise. But it needs to be emphasised that it is not seen as a purely stand alone product but rather as an aid or adjuvant therapy combined with highly toxic chemotherapy agents or other inhibitors which also exhibit severe side effects such as Bevacizumab and Ipilimumab.
Severe and potentially fatal side effects from Nivolumab alone occurs in 14% of all patients treated. These include autoimmune adverse events such as pneumonitis, vitiligo, colitis, hepatitis, hypophysitis and thyroiditis. Toxicity is the main objection to the use of inhibitors generally.
So what relevance does all this have for non-toxic cancer vaccines such as Scancell's SCIB1? Very little. Victoria Brentville, Rachael Metheringham and Barbara Gunn from the University of Nottingham together with Scancell's Lindy Durrant have shown that the high avidity T Cell response generated by Scancell's ImmunoBody vaccine platform is sufficient to overwhelm the PD-1 blockade, eradicate tumours and retain an accurate immune memory. This latter allows a re-booting of the immune system with immediate and equal force should a booster jab be required at some time in the future.
[Published courtesy of LadyBio - DTM Scancell Chat]
Evening ! The financial times described scancell as 'tightly held' back in October last year ... Taking into consideration the 'news' since then and, if scancell had a voice, do you think it would be fairly high pitched by now !! Take care !!
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.